PMID- 37950855
OWN - NLM
STAT- MEDLINE
DCOM- 20240122
LR  - 20240202
IS  - 1096-8652 (Electronic)
IS  - 0361-8609 (Linking)
VI  - 99
IP  - 2
DP  - 2024 Feb
TI  - Comparative pharmacovigilance assessment of adverse events associated with the 
      use of hydroxyurea, L-glutamine, voxelotor, and crizanlizumab in sickle cell 
      disease.
PG  - E37-E41
LID - 10.1002/ajh.27153 [doi]
AB  - Using disproportionality analysis, this study compared the adverse events (AEs) 
      associated with the use of the new agents (e.g., L-glutamine, voxelotor, and 
      crizanlizumab) to the commonly used medication, hydroxyurea, in sickle cell 
      disease. We found that the most frequent drug-related AEs observed in this 
      real-world study were consistent with those in the HOPE (voxelotor) and SUSTAIN 
      (crizanlizumab) trials, but the rates of AEs were lower. Our study demonstrates 
      that the most common AEs and symptoms of an increased risk associated with the 
      individual drugs varied by treatment. Disproportionate reporting signals of 
      drug-related AEs may also capture information that is independent of subjective 
      measures of patient-reported symptoms. Our study highlights the important need 
      for facilitating patient-physician communication in routine clinical care to 
      understand patient-reported symptoms.
CI  - (c) 2023 Wiley Periodicals LLC.
FAU - Chen, Ming
AU  - Chen M
AUID- ORCID: 0000-0003-3215-8657
AD  - Institute of Health Outcomes and Policy, University of Tennessee Health Science 
      Center, Memphis, Tennessee, USA.
AD  - Center for Health System Improvement, University of Tennessee Health Science 
      Center, Memphis, Tennessee, USA.
FAU - Hankins, Jane S
AU  - Hankins JS
AUID- ORCID: 0000-0003-4439-7321
AD  - Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, 
      Memphis, Tennessee, USA.
AD  - Department of Hematology, St. Jude Children's Research Hospital, Memphis, 
      Tennessee, USA.
AD  - Center for Sickle Cell Disease, University of Tennessee Health Science Center, 
      Memphis, Tennessee, USA.
FAU - Zhang, Min
AU  - Zhang M
AD  - Vanke School of Public Health, Tsinghua University, Beijing, China.
FAU - Ataga, Kenneth I
AU  - Ataga KI
AUID- ORCID: 0000-0002-4501-9982
AD  - Center for Sickle Cell Disease, University of Tennessee Health Science Center, 
      Memphis, Tennessee, USA.
AD  - Department of Medicine - Hematology, University of Tennessee Health Science 
      Center, Memphis, Tennessee, USA.
LA  - eng
PT  - Letter
DEP - 20231111
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
RN  - X6Q56QN5QC (Hydroxyurea)
RN  - L7451S9126 (crizanlizumab)
RN  - 3ZO554A4Q8 (voxelotor)
RN  - 0RH81L854J (Glutamine)
RN  - 0 (Benzaldehydes)
RN  - 0 (Pyrazines)
RN  - 0 (Pyrazoles)
RN  - 0 (Antibodies, Monoclonal, Humanized)
SB  - IM
MH  - Humans
MH  - *Hydroxyurea/adverse effects
MH  - Glutamine
MH  - Pharmacovigilance
MH  - *Anemia, Sickle Cell/drug therapy/complications
MH  - *Benzaldehydes
MH  - *Pyrazines
MH  - *Pyrazoles
MH  - *Antibodies, Monoclonal, Humanized
EDAT- 2023/11/11 20:54
MHDA- 2024/01/22 06:43
CRDT- 2023/11/11 12:12
PHST- 2023/10/24 00:00 [revised]
PHST- 2023/09/18 00:00 [received]
PHST- 2023/10/25 00:00 [accepted]
PHST- 2024/01/22 06:43 [medline]
PHST- 2023/11/11 20:54 [pubmed]
PHST- 2023/11/11 12:12 [entrez]
AID - 10.1002/ajh.27153 [doi]
PST - ppublish
SO  - Am J Hematol. 2024 Feb;99(2):E37-E41. doi: 10.1002/ajh.27153. Epub 2023 Nov 11.